AFLIBERCEPT:Addressing the Unmet Needin Neovascular Age-relatedMacular Degeneration (nAMD)
Today, despite the effectiveness of anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapies, frequent injections and monitoring remain major challenges that can contribute to undertreatment and subsequent vision loss.1
Also, pharmacokinetic studies have shown that aflibercept provides greater suppression of plasma-free VEGF than bevacizumab and ranibizumab.2
